不同基础疾病下肺孢子菌肺炎的特征与预后因素:回顾性多中心研究
该多中心回顾性研究纳入2011至2021年481例确诊或临床诊断的肺孢子菌肺炎(PcP)患者,评估基础免疫抑制疾病对临床表现和死亡率的影响。在HIV阴性人群中,实体肿瘤、免疫介导炎症性疾病(IMIDs)、长期使用糖皮质激素、痰/BAL涂片见囊虫及入院SOFA评分与90天死亡率独立相关。既往糖皮质激素治疗是唯一与90天死亡率相关的免疫抑制剂,尤其在IMIDs患者中。
要点
- HIV阴性PcP患者中,实体肿瘤和IMIDs与90天死亡率独立相关。
- 长期糖皮质激素暴露(尤其泼尼松≥10 mg/日)与90天死亡率独立相关。
- IMIDs患者需考虑PcP预防,重症肺炎时应早期考虑PcP治疗。
核心结论
- 在HIV阴性PcP患者中,诊断前长期使用糖皮质激素与90天死亡率增加独立相关,尤其在IMIDs患者中。
- 结果提示IMIDs患者需要PcP预防,且重症肺炎时应早期考虑PcP治愈性治疗。
研究设计与样本
- 共纳入481例患者,其中180例(37.4%)为确诊PcP,301例(62.6%)为临床诊断PcP。
主要发现
- IMIDs或实体肿瘤患者在第90天预后显著差于其他PcP患者。
- HIV阴性人群中,实体肿瘤(OR 5.47;95%CI 2.16-14.1;P<.001)与90天死亡率独立相关。
- IMIDs(OR 2.19;95%CI 1.05-4.60;P=.037)与90天死亡率独立相关。
- 长期糖皮质激素暴露(OR 2.07;95%CI 1.03-4.31;P=.045)与90天死亡率独立相关。
- 痰/BAL涂片见囊虫(OR 1.92;95%CI 1.02-3.62;P=.043)及入院SOFA评分(OR 1.58;95%CI 1.39-1.82;P<.001)与90天死亡率独立相关。
关键数值与推荐
- 既往糖皮质激素治疗是唯一与90天死亡率相关的免疫抑制剂(OR 1.67;95%CI 1.03-2.71;P=.035)。
- 泼尼松每日剂量≥10 mg时OR 1.80(95%CI 1.14-2.85;P=.010)。
临床怎么用
- 对IMIDs患者应评估PcP预防的必要性。
- IMIDs患者出现重症肺炎时应早期考虑PcP治愈性治疗。
- HIV阴性PcP患者需关注实体肿瘤、长期糖皮质激素使用及高SOFA评分等不良预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumocystis jirovecii pneumonia (PcP) remains associated with high rates of mortality, and the impact of immunocompromising underlying disease on the clinical presentation, severity, and mortality of PcP has not been adequately evaluated. RESEARCH QUESTION: Does the underlying disease and immunosuppression causing PcP impact the outcome and clinical presentation of the disease? STUDY DESIGN AND METHODS: In this multicenter retrospective observational study, conducted from January 2011 to December 2021, all consecutive patients admitted with a proven or probable diagnosis of PcP according to the European Organisation for Research and Treatment of Cancer consensus definitions were included to assess the epidemiology and impact of underlying immunosuppressive diseases on overall and 90-day mortality. RESULTS: Overall, 481 patients were included in the study; 180 (37.4%) were defined as proven PcP and 301 (62.6%) were defined as probable PcP. Patients with immune-mediated inflammatory diseases (IMIDs) or solid tumors had a statistically poorer prognosis than other patients with PcP at day 90. In multivariate analysis, among the HIV-negative population, solid tumor underlying disease (OR, 5.47; 95% CI, 2.16-14.1; P < .001), IMIDs (OR, 2.19; 95% CI, 1.05-4.60; P = .037), long-term corticosteroid exposure (OR, 2.07; 95% CI, 1.03-4.31; P = .045), cysts in sputum/BAL smears (OR, 1.92; 95% CI, 1.02-3.62; P = .043), and SOFA score at admission (OR, 1.58; 95% CI, 1.39-1.82; P < .001) were independently associated with 90-day mortality. Prior corticotherapy was the only immunosuppressant associated with 90-day mortality (OR, 1.67; 95% CI, 1.03-2.71; P = .035), especially for a prednisone daily dose ≥ 10 mg (OR, 1.80; 95% CI, 1.14-2.85; P = .010). INTERPRETATION: Among patients who were HIV-negative, long-term corticosteroid prior to PcP diagnosis was independently associated with increased 90-day mortality, specifically in patients with IMIDs. These results highlight both the needs for PcP prophylaxis in patients with IMIDs and to early consider PcP curative treatment in severe pneumonia among patients with IMIDs.
引用
- Lécuyer R, Issa N, Camou F, et al. Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease: A Retrospective Multicenter Study. Chest. 2024. PMID: 38215935. doi:10.1016/j.chest.2024.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。